Lynparza stalls pancreatic cancer in patients with BRCA mutations: study

CHICAGO (Reuters) – AstraZeneca and Merck & Co’s Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go longer without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday.

BRCA mutations are typically linked with breast and ovarian cancers, but occur in other cancers as well.

Lynparza was tested against a placebo as a maintenance therapy in 154 patients with metastatic pancreatic cancer whose tumors had not progressed after chemotherapy.

Those who received the Merck and AstraZeneca drug on average went 7.4 months before their disease began to worsen, a measure known as progression-free survival (PFS). That compared with a median PFS of 3.8 months for placebo, according to data presented at the American College of Clinical Oncology meeting in Chicago.

Patients had been screened for BRCA1 or BRCA2 mutations using Myriad Genetics’ BRACAnalysis CDx test.

For the 6-7% of pancreatic cancer patients who carry these inherited mutations, the finding is significant.

“This was clearly positive,” said Dr. Eileen O’Reilly, a pancreatic cancer expert at Memorial Sloan Kettering Cancer Center in New York, who helped lead the study.

O’Reilly said the findings reinforce new guidelines from the National Comprehensive Cancer Network recommending universal BRCA testing for all patients with pancreatic cancer.

Mutations in BRCA genes impair the ability to repair DNA damage, which can drive cancer growth. Lynparza and other drugs in the class known as PARP inhibitors exploit this weakness, keeping cancer cells damaged by chemotherapy from repairing themselves. Lynparza became the first PARP drug to reach the market with a U.S. approval for ovarian cancer in late 2014.

An interim analysis, however, showed the drug made no significant difference in overall survival.

“We typically see about 10 to 12 months” for overall survival in these patients, O’Reilly said. Patients in both arms of the Lynparza study lived about 18 to 19 months.

Dr. Roy Baynes, Merck’s chief medical officer, said the hope is that a delay in cancer progression will ultimately translate into longer survival.

“In pancreatic cancer, progress has been really slow so this is really quite exciting data for patients who have the BRCA mutation,” Baynes said.

Lynparza is an important growth driver for AstraZeneca, generating $647 million in sales last year. Analysts have forecast $2.5 billion in revenue from the drug in 2023, according to Refinitiv data. [L3N20L2TP] Use in pancreatic cancer in addition to breast and ovarian cancer would boost Lynparza sales and cement its lead over rival PARP inhibitors Rubraca from Clovis Oncology, GSK’s Zejula and Pfizer’s talazoparib.

Reporting by Julie Steenhuysen; additional reporting by Ludwig Burger in Frankfurt; editing by Bill Berkrot

Source

more recommended stories

  • South Africa to roll out sweeping health reform in stages

    PRETORIA (Reuters) – A proposed move.

  • FDA classifies Edwards Lifesciences Sapien delivery system recall as severest

    (Reuters) – The U.S. Food and.

  • Plastic particles in drinking water present ‘low’ risk: WHO

    GENEVA (Reuters) – Microplastics contained in.

  • AstraZeneca’s Imfinzi misses main goal of advanced lung cancer study

    FILE PHOTO: A sign is seen.

  • AstraZeneca diabetes drug shows promise in heart failure

    (Reuters) – AstraZeneca (AZN.L) made strides.

  • Study prompts call for lower fluoride consumption by pregnant women

    (Reuters Health) – Adding fluoride to.

  • CDC investigates lung illnesses linked to e-cigarette use

    FILE PHOTO: A man vapes outside.

  • E.coli in water forces Tokyo to cancel swimming at Paratriathlon World Cup

    TOKYO (Reuters) – High levels of.

  • E.coli risk forces Tokyo to cancel swim events at Paratriathlon World Cup

    TOKYO (Reuters) – High levels of.

  • First two Ebola cases confirmed in Congo’s South Kivu – officials

    FILE PHOTO: Children look at a.

  • Surgical training programs not supportive of new parents

    (Reuters Health) – Surgical residents say.

  • Liver disease related to obesity and diabetes rising in U.S.

    (Reuters Health) – The only liver.

  • Ebola ‘no longer incurable’ as Congo trial finds drugs boost survival

    LONDON (Reuters) – Scientists are a.

  • Scientists hail promise of first effective Ebola treatments in Congo trial

    LONDON (Reuters) – Scientists are a.

  • China cuts 2019/20 corn use forecast by 2 million tonnes due to African swine fever

    Corn kernels are seen at a.

  • WHO says no new Ebola cases in Goma, vaccinates over 1,300

    FILE PHOTO: A young woman reacts.

  • Dengue death toll rises in Malaysia, number of cases close to double

    KUALA LUMPUR (Reuters) – Malaysia saw.

  • Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting Novartis

    (Reuters) – A U.S. judge on.

  • AstraZeneca’s Tagrisso helps lung cancer patients live longer: study

    (Reuters) – AstraZeneca Plc said on.

  • Study shows Apple devices in combo with apps could identify dementia

    FILE PHOTO: The new Apple iPhone.

  • Moving during early pregnancy may increase preterm birth risk

    (Reuters Health) – Moving to a.

  • Drug assistance programs offer little charity to uninsured

    (Reuters Health) – Many patients who.

  • In extreme heat, electric fans inadvisable unless it’s humid

    In extreme heat, electric fans may.

  • Trump administration considers September unveiling of healthcare plan: WSJ

    FILE PHOTO: U.S. President Donald Trump.

  • Bulgaria to compensate owners who cull pigs to help stamp out swine fever

    FILE PHOTO: A pig rests at.

  • Yellow lens glasses don’t improve drivers’ night vision

    (Reuters Health) – – Touted to.

  • U.S. FDA approves Daiichi Sankyo’s treatment for rare joint tumor

    (Reuters) – The U.S. Food and.

  • For some surgeries, hospital rankings not tied to better outcomes

    (Reuters Health) – When it comes.

  • Congo says Rwanda has closed border near Goma

    Congolese customs agents gather at the.

  • Pluristem gets positive results from radiation treatment trials

    TEL AVIV (Reuters) – Israel’s Pluristem Therapeutics.

  • Congress seeks briefing on potential threat to U.S. heparin supply

    WASHINGTON (Reuters) – Leaders of the.

  • U.S. judge blocks Medicaid work requirements in New Hampshire

    (Reuters) – A federal judge on.